[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan E. Dickinson B.Sc., M.B.A.", "age": 56, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 129517, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 51, "title": "Executive VP & COO", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 499786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 62, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 570463, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 60, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 60, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 64, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie  Cornen", "title": "Vice President of Investor Relations, Communication & Commercial Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.91, "open": 1.895, "dayLow": 1.89, "dayHigh": 1.96, "regularMarketPreviousClose": 1.91, "regularMarketOpen": 1.895, "regularMarketDayLow": 1.89, "regularMarketDayHigh": 1.96, "payoutRatio": 0.0, "beta": 0.512, "forwardPE": 4.2000003, "volume": 12665, "regularMarketVolume": 12665, "averageVolume": 194865, "averageVolume10days": 23550, "averageDailyVolume10Day": 23550, "bid": 1.95, "ask": 1.94, "bidSize": 1, "askSize": 1, "marketCap": 174216320, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 3.511, "allTimeHigh": 11.95, "allTimeLow": 1.29, "priceToSalesTrailing12Months": 13.7873, "fiftyDayAverage": 1.96708, "twoHundredDayAverage": 2.015325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 141180240, "profitMargins": 0.0, "floatShares": 60140336, "sharesOutstanding": 92177948, "sharesShort": 220987, "sharesShortPriorMonth": 53076, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.00154, "shortRatio": 0.46, "shortPercentOfFloat": 0.0027, "impliedSharesOutstanding": 92177948, "bookValue": 0.056, "priceToBook": 33.75, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -46051000, "trailingEps": -0.64, "forwardEps": 0.45, "enterpriseToRevenue": 11.173, "enterpriseToEbitda": -2.837, "52WeekChange": 0.0052632093, "SandP52WeekChange": 0.13287461, "quoteType": "EQUITY", "currentPrice": 1.89, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.154, "targetMedianPrice": 5.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 60027000, "totalCashPerShare": 0.651, "ebitda": -49771000, "totalDebt": 27029000, "quickRatio": 2.081, "currentRatio": 2.208, "totalRevenue": 12636000, "debtToEquity": 525.447, "revenuePerShare": 0.15, "returnOnAssets": -0.25922, "returnOnEquity": -2.71367, "grossProfits": -30788000, "freeCashflow": -20764000, "operatingCashflow": -41096000, "revenueGrowth": -0.606, "grossMargins": -2.43653, "ebitdaMargins": 0.0, "operatingMargins": -5.23189, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -1.04712, "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "regularMarketTime": 1764968401, "exchange": "NMS", "messageBoardId": "finmb_426137", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 1.89, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "postMarketChangePercent": -0.5291, "postMarketPrice": 1.88, "postMarketChange": -0.00999999, "regularMarketChange": -0.02, "regularMarketDayRange": "1.89 - 1.96", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 194865, "fiftyTwoWeekLowChange": 0.41999996, "fiftyTwoWeekLowChangePercent": 0.28571424, "fiftyTwoWeekRange": "1.47 - 3.511", "fiftyTwoWeekHighChange": -1.6209999, "fiftyTwoWeekHighChangePercent": -0.46169183, "fiftyTwoWeekChangePercent": 0.52632093, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1764974877, "earningsTimestamp": 1763040600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "earningsCallTimestampStart": 1758110400, "earningsCallTimestampEnd": 1758110400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.64, "epsForward": 0.45, "epsCurrentYear": -0.64467, "priceEpsCurrentYear": -2.9317324, "fiftyDayAverageChange": -0.07708001, "fiftyDayAverageChangePercent": -0.03918499, "twoHundredDayAverageChange": -0.12532508, "twoHundredDayAverageChangePercent": -0.06218604, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2025-12-06"}]